An Opportunity to Advance Cannabis Science—DEA Rescheduling
This Viewpoint discusses the regulatory and financial barriers to cannabis research, and the potential changes to these barriers if cannabis is reclassified as a Schedule III drug.
Authors
- Anshul V. Puli (ORCID: https://orcid.org/0000-0002-1303-4205)
- Kevin P. Hill (ORCID: https://orcid.org/0000-0002-0143-8739)
Institutions
- Beth Israel Deaconess Medical Center (US)
- Harvard University (US)
Publication Details
- Journal
- JAMA Psychiatry
- Published
- 2025-02-05
- DOI
- https://doi.org/10.1001/jamapsychiatry.2024.4691
- Citations
- 2
- Primary Topic
- Cannabis and Cannabinoid Research
- Type
- article
- Field-Weighted Citation Impact
- 2.79